MENU
ACTU
AS OF
Dec 24 closing price
Price
$6.56
Change
-$0.05 (-0.76%)
Capitalization
152.48M
61 days until earnings call
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
ACTU
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Actuate Therapeutics (ACTU) Ownership - Who owns Actuate Therapeutics?

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3)... Show more

#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
152.48M
P/E Ratio
19.29
Total Cash
16.92M
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
0.73
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

ACTU
Capitalization
152M
P/E Ratio
19.29
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
16.9M
Total Cash/Share
0.73
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
10.9M
P/B Ratio
13.95
Cash Flow
N/A
Earnings
0.34
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
23
Current Ratio
2.74
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-24.1M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-150.86
Shares Held By Institutions
85M
Shares Outstanding - Current
23.2M
Total Liabilities
6.78M
Total Volume MTD
N/A
Value
-1
Gain YTD
-17.588
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
ACTU
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ACTU showed earnings on December 03, 2025. You can read more about the earnings report here.
View AI-Driven Trading for ACTU
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details